In patients with chronic idiopathic thrombocytopenic purpura and other platelet abnormalities, surface counting of platelets labelled with chromium-51 has given inconsistent results. There is still considerable uncertainty regarding platelet destruction in these patients; in some cases the liver, and in others the spleen, appears to be the predominant organ of destruction.lA Heyns et a.5 and Klonizakis et al. 6 studied the distribution and destruction of indium-111 ("'In) labelled platelets in normal subjects using the technique of quantitative scanning. We describe the use of this technique in a study of platelet kinetics in a series of haematological patients with platelet abnormalities.
Material and methods
Patients with a variety of haematological disorders were referred for platelet studies (Table) .
Platelets were prepared for incubation with "Illnoxine by one of the three techniques described by Klonizakis et al.6 In most of the patients, platelets were resuspended in dextrose saline; in some, resuspension was in plasma saline or plasma. We tLabelled isologous platelets injected.
T, = time taken for circulating labelled platelet level to fall to halfthe 30-minute value. ITP = Idiopathic thrombocytopenic purpura. group 2 show approximately equal uptake in marrow Discussion and spleen, similar to normals;6 and group 3 patients show increased splenic uptake with variable and In thrombocytopenic patients, the difficulty of uncertain marrow uptake.
incorporating "'In in platelets in sufficient quantity "'In uptake in the liver is shown for all subjects for subsequent external scanning is accentuated in Figure 4 . With the exception of one patient with because even trace quantities of plasma or anions idiopathic thrombocytopenic purpura, liver "'1In such as citrate or phosphate compete with the uptake was less than in the spleen and rose only platelets for "'In. The use of dextrose saline as a reslightly during the duration of the platelet life span. The patients in group I showed abnormal platelet pooling in the spleen, with a low initial blood "'In recovery, a high initial splenic "'In, and a 'flat' survival curve with essentially normal life span; it is reasonable to suppose that the platelets are normal and that the high splenic "'In is a reflection of increased splenic pooling capacity. In these cases the estimated bone marrow platelet destruction seems less than norrnal, possibly as a result of a shift towards splenic destruction resulting from increased splenic activity; that is, although splenic platelet destruction is increased, total destruction is not, and platelets are not destroyed prematurely. In group 2, on the other hand, bone marrow and splenic destruction appear to be equally accelerated, such that the relative proportion of platelets destroyed at each site remains more or less normal. In these patients, the primary abnormality is presumably in the platelet, as is borne out by the curvilinear shape of the survival curves and the clinical conditions. In group 3, platelet survival is severely reduced, and splenic and marrow accumulation of the effete platelets is markedly abnormal. In this group, the assumption upon which the estimates of splenic and marrow platelet destruction are based is likely to be unjustified. As survival is so short, the distinction between pooling, sequestration (ie, prolonged platelet hold-up), and destruction becomes impossible. Quantification of the bone marrow uptake must be interpreted with caution; the initial sum of blood, spleen, and liver quantities is well below 100% of the dose. Whether this is because bone marrow uptake is very rapid, or because platelet uptake occurs at other, unidentified, sites, is not known. The scan shown in Fig. 5 , showing "'In uptake in the kidneys of a patient suffering from thrombotic thrombocytopenic purpura, suggests that such alternative uptake may occur in this disease. Quantification of liver "'In uptake suggests that, even in subjects with abnormal platelet turnover, the liver is not an important organ for platelet de- struction. The only patient to show a substantial liver uptake had received isologous platelets. The significance of increased liver uptake is further limited by the likelihood that platelets severely damaged in the labelling procedure are removed rapidly by the liver.8
The small series of patients investigated does not allow us to draw many conclusions as to the pathophysiology of platelet destruction, but this study has demonstrated the advantages of "'In labelling, together with sequential quantitative scanning, in obtaining more meaningful information than from surface counting in the interpretation of spleen function in relation to platelet kinetics.
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